{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:19:30Z","timestamp":1780078770488,"version":"3.54.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.xjidi.2023.100192","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T02:28:42Z","timestamp":1676860122000},"page":"100192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the Impact of Exclusion Criteria on the Generalizability of Hidradenitis Suppurativa Treatment Research"],"prefix":"10.1016","volume":"3","author":[{"given":"Jalal","family":"Maghfour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Parks-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat H.","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2023.100192_bib1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","article-title":"Treatment of hidradenitis suppurativa with etanercept injection","volume":"146","author":"Adams","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.xjidi.2023.100192_bib2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies","volume":"186","author":"Alavi","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2023.100192_bib3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00019442-200303000-00006","article-title":"Impact of study design and patient population on outcomes from cholinesterase inhibitor trials","volume":"11","author":"Anand","year":"2003","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.xjidi.2023.100192_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cdp.2005.12.001","article-title":"Recruitment and participation in clinical trials: socio-demographic, rural\/urban, and health care access predictors","volume":"30","author":"Baquet","year":"2006","journal-title":"Cancer Detect Prev"},{"key":"10.1016\/j.xjidi.2023.100192_bib5","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","article-title":"Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial","volume":"156","author":"Bechara","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.xjidi.2023.100192_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14674","article-title":"Pregnancy and breastfeeding in hidradenitis suppurativa: a review of medication safety","volume":"34","author":"Collier","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.xjidi.2023.100192_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/1740774510396742","article-title":"Impact and costs of targeted recruitment of minorities to the National Lung Screening Trial","volume":"8","author":"Duda","year":"2011","journal-title":"Clin Trials"},{"key":"10.1016\/j.xjidi.2023.100192_bib9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/1740774514538706","article-title":"Screen failure data in clinical trials: are screening logs worth it?","volume":"11","author":"Elm","year":"2014","journal-title":"Clin Trials"},{"key":"10.1016\/j.xjidi.2023.100192_bib10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/DSS.0000000000002112","article-title":"Intralesional triamcinolone may not be beneficial for treating acute hidradenitis suppurativa lesions: A double-blind, randomized, placebo-controlled trial","volume":"46","author":"Fajgenbaum","year":"2020","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.xjidi.2023.100192_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1258\/om.2009.090002","article-title":"Drugs in Pregnancy and Lactation 8th Edition: A Reference Guide to Fetal and Neonatal Risk","volume":"2","author":"Freyer","year":"2009","journal-title":"Obstet Med"},{"key":"10.1016\/j.xjidi.2023.100192_bib12","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/MCG.0b013e31825f2807","article-title":"Infliximab and adalimumab use during breastfeeding","volume":"46","author":"Fritzsche","year":"2012","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.xjidi.2023.100192_bib13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaad.2017.02.005","article-title":"Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis","volume":"77","author":"Garg","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100192_bib14","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2023.100192_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100192_bib16","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40257-020-00537-9","article-title":"Botulinum Toxin Type B for hidradenitis suppurativa: a randomised, double-blind, placebo-controlled pilot study","volume":"21","author":"Grimstad","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.xjidi.2023.100192_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cct.2014.08.004","article-title":"Strategies addressing barriers to clinical trial enrollment of underrepresented populations: a systematic review","volume":"39","author":"Heller","year":"2014","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.xjidi.2023.100192_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/17512433.2020.1743175","article-title":"Evolution of the inclusion\/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis","volume":"13","author":"Hsu","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.xjidi.2023.100192_bib19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/geront\/gnv118","article-title":"African Americans and clinical research: evidence concerning barriers and facilitators to participation and recruitment recommendations","volume":"57","author":"Hughes","year":"2017","journal-title":"Gerontologist"},{"key":"10.1016\/j.xjidi.2023.100192_bib20","first-page":"206","article-title":"Inclusion and exclusion criteria of clinical trials for insomnia","volume":"7","author":"Huls","year":"2018","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.xjidi.2023.100192_bib21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 targeting IL-1\u03b1 for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2023.100192_bib22","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.xjidi.2023.100192_bib23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two Phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2023.100192_bib24","doi-asserted-by":"crossref","first-page":"B19","DOI":"10.1016\/j.jid.2021.07.121","article-title":"LB791 Avacopan, a highly selective small molecule inhibitor of c5a receptor, in patients with Hidradenitis Suppurativa: initial results from a randomized, double-blind, placebo-controlled, phase 2 study (aurora)","volume":"141","author":"Kirby","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2023.100192_bib25","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000486741","article-title":"Hidradenitis suppurativa: disease burden and etiology in skin of color","volume":"233","author":"Lee","year":"2017","journal-title":"Dermatology"},{"key":"10.1016\/j.xjidi.2023.100192_bib26","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jaad.2009.07.048","article-title":"Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long-pulsed neodymium:yttrium-aluminium-garnet laser","volume":"62","author":"Mahmoud","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100192_bib27","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s11606-011-1672-2","article-title":"Is primary care providers\u2019 trust in socially marginalized patients affected by race?","volume":"26","author":"Moskowitz","year":"2011","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.xjidi.2023.100192_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2023.100192_bib29","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1016\/j.jid.2021.03.037","article-title":"No evident systemic terminal complement pathway activation in hidradenitis suppurativa","volume":"141","author":"Prens","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2023.100192_bib30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000504911","article-title":"Race and ethnicity gaps in global hidradenitis suppurativa clinical trials","volume":"237","author":"Price","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.xjidi.2023.100192_bib31","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1353\/hpu.0.0185","article-title":"Physicians' implicit and explicit attitudes about race by MD race, ethnicity, and gender","volume":"20","author":"Sabin","year":"2009","journal-title":"J\u00a0Health Care Poor Underserved"},{"key":"10.1016\/j.xjidi.2023.100192_bib32","first-page":"26","article-title":"Eligibility criteria may hinder black patients in pancreatic cancer trials","volume":"43","author":"Samson","year":"2021","journal-title":"Oncology Times"},{"key":"10.1016\/j.xjidi.2023.100192_bib33","doi-asserted-by":"crossref","DOI":"10.5070\/D3223030360","article-title":"Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial","volume":"22","author":"Scheinfeld","year":"2016","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.xjidi.2023.100192_bib34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: A randomized clinical trial [published correction appears in JAMA Dermatol 2017;153:950]","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2023.100192_bib35","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","article-title":"Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review","volume":"297","author":"Van Spall","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.xjidi.2023.100192_bib36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100192_bib37","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jaad.2018.06.032","article-title":"Aggravation of mild axillary hidradenitis suppurativa by microwave ablation: results of a randomized intrapatient-controlled trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100192_bib38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijwd.2020.12.013","article-title":"Bridging racial differences in the clinical encounter: how implicit bias and stereotype threat contribute to health care disparities in the dermatology clinic","volume":"7","author":"Wilson","year":"2021","journal-title":"Int J Womens Dermatol"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026723000140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026723000140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:04:15Z","timestamp":1763021055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026723000140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2667026723000140"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2023.100192","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the Impact of Exclusion Criteria on the Generalizability of Hidradenitis Suppurativa Treatment Research","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2023.100192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100192"}}